Impact of factors affecting the residual tumor size diagnosed by MRI following neoadjuvant chemotherapy in comparison to pathology
Authors:
- 28 October 2013
- journal article
- research article
- Published by Wiley in Journal of Surgical Oncology
- Vol. 109 (2) , 158-167
Abstract
Background and Objectives: To investigate accuracy of magnetic resonance imaging (MRI) for measuring residual tumor size in breast cancer patients receiving neoadjuvant chemotherapy (NAC).Methods: Ninety‐eight patients were studied. Several MRI were performed during NAC for response monitoring, and the residual tumor size was measured on last MRI after completing NAC. Covariates, including age, tumor characteristics, biomarkers, NAC regimens, MRI scanners, and time from last MRI to operation, were analyzed. Univariate and Multivariate linear regression models were used to determine the predictive value of these covariates for MRI‐pathology size discrepancy as the outcome measure.Results: The mean (±SD) of the absolute difference between MRI and pathological residual tumor size was 1.0 ± 2.0 cm (range, 0–14 cm). Univariate regression analysis showed tumor type, morphology, HR status, HER2 status, and MRI scanner (1.5 T or 3.0 T) were significantly associated with MRI‐pathology size discrepancy (all P < 0.05). Multivariate regression analyses demonstrated that only tumor type, tumor morphology, and biomarker status considering both HR and HER‐2 were independent predictors (P = 0.0014, 0.0032, and 0.0286, respectively).Conclusion: The accuracy of MRI in evaluating residual tumor size depends on tumor type, morphology, and biomarker status. The information may be considered in surgical planning for NAC patients. J. Surg. Oncol. 2014 109:158–167.Keywords
Funding Information
- NIH/NCI R01 (CA127927)
- California Breast Cancer Research Program (16GB-0056)
This publication has 61 references indexed in Scilit:
- Diagnostic Performance of Magnetic Resonance Imaging for Assessing Tumor Response in Patients With HER2-Negative Breast Cancer Receiving Neoadjuvant Chemotherapy is Associated With Molecular Biomarker ProfileClinical Breast Cancer, 2012
- Breast Cancer: Evaluation of Response to Neoadjuvant Chemotherapy with 3.0-T MR ImagingRadiology, 2011
- Magnetic Resonance Imaging Response Monitoring of Breast Cancer During Neoadjuvant Chemotherapy: Relevance of Breast Cancer SubtypeJournal of Clinical Oncology, 2011
- American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast CancerJournal of Clinical Oncology, 2010
- The Relevance of Breast Cancer Subtypes in the Outcome of Neoadjuvant ChemotherapyAnnals of Surgical Oncology, 2010
- Residual Breast Cancer Diagnosed by MRI in Patients Receiving Neoadjuvant Chemotherapy with and Without BevacizumabAnnals of Surgical Oncology, 2009
- Impact of MRI-Evaluated Neoadjuvant Chemotherapy Response on Change of Surgical Recommendation in Breast CancerAnnals of Surgery, 2009
- Using MRI to plan breast-conserving surgery following neoadjuvant chemotherapy for early breast cancerBritish Journal of Cancer, 2008
- American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast CancerJournal of Clinical Oncology, 2007
- Twenty-Year Follow-up of a Randomized Study Comparing Breast-Conserving Surgery with Radical Mastectomy for Early Breast CancerNew England Journal of Medicine, 2002